Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month ended April 30, 2024
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a cover sheet incorporating an exhibit titled "Quarterly Activities/Appendix 4C Cash Flow Report" (Exhibit 99.1), but the detailed financial data within that exhibit is not included in the provided text.
Material Changes
The filing text does not contain information regarding material changes versus the prior comparable period.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, specific risks, contingencies, or unusual items. The document is primarily administrative, noting the incorporation of the report into Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the contents of Exhibit 99.1 ("Quarterly Activities/Appendix 4C Cash Flow Report") to obtain actual cash flow figures.
- Confirm the status of the referenced Registration Statements (Form S-8 and Form F-3) for potential capital raising activities.
- Review the full text of the incorporated exhibit for any updates on the company's development stage operations.